MicroRNA 15a and 16 Regulate Proteostasis in Non-Small Cell Lung Cancer

  • FASEB Bioadv. 2026 May 2:8:e70111. doi: 10.1096/fba.2026-00075.
Patrick J Ryan  1 ,  Bethany C Guerra  1 ,  Peter Nghiem  2 ,  Steven E Riechman  1 ,  Mariana Janini Gomes  1 ,  James D Fluckey  1
Affiliations
  • 1. Muscle Biology Laboratory, Department of Kinesiology and Sports Management Texas A&M University College Station Texas USA.
  • 2. Department of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences Texas A&M University College Station Texas USA.
Abstract

Aberrant anabolic activity is critical to tumor biology; however, much remains to be learned about the regulators of protein anabolism in Cancer and how this regulation may affect Cancer pathophysiology. MicroRNA (miRNA), a family of small nucleotide regulatory molecules, may serve as a potential source of proteostatic regulation. Here, we examined the ability of two co-transcribed miRNA species, miR15a and miR16 (jointly described as miR15a/16) to regulate protein handling and pathophysiology in Non-Small Cell Lung Cancer (NSCLC). We found that miR15a/16 regulates genes in numerous metabolic and pathological pathways, including those related to protein metabolism. Transfection of cellular models of NSCLC with miR15a/16 mimetics caused reductions in both cell growth and protein synthesis rates. These findings indicate that miR15a/16 acts as regulators of protein anabolism in NSCLC, serving as novel metabolic regulators and potential clinical therapeutic targets for malignant Lung Cancer.

Keywords
anabolism; cancer; metabolism; microRNA; proteostasis.
Products